Viatris Inc (VTRS)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit Dividendenhistorie

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Viatris Inc Stock (VTRS) Company Profile

Healthcare (1113)

(724) 514-1465

1000 MYLAN BOULEVARD, CANONSBURG

Nächster Verdiensttermin

Neueste SEC-Einreichungen

VTRS's Discussions on Twitter

Compare VTRS vs TAK, ZTS, HLN, TEVA, UTHR

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
VTRS Viatris Inc	13.37	15.39B	14.29B	-3.51B	1.85B	-2.9603
TAK Takeda Pharmaceutical Co Adr	18.06	57.06B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	116.63	49.23B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	9.75	43.52B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	29.78	34.68B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	532.53	23.34B	3.18B	1.33B	1.04B	27.90

Viatris Inc Stock (VTRS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-02-09	Hochstufung	UBS	Neutral → Buy
2026-01-16	Hochstufung	Argus	Hold → Buy
2025-12-09	Eingeleitet	Barclays	Overweight
2025-10-15	Eingeleitet	Truist	Buy
2025-06-06	Eingeleitet	Goldman	Neutral
2024-07-19	Fortgesetzt	Jefferies	Buy
2023-10-23	Herabstufung	BofA Securities	Neutral → Underperform
2023-06-23	Herabstufung	Barclays	Equal Weight → Underweight
2023-04-24	Herabstufung	Barclays	Overweight → Equal Weight
2023-02-17	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2023-01-27	Hochstufung	Jefferies	Hold → Buy
2022-11-10	Hochstufung	UBS	Sell → Neutral
2022-11-08	Hochstufung	Piper Sandler	Underweight → Neutral
2022-10-21	Fortgesetzt	Jefferies	Hold
2022-06-14	Eingeleitet	UBS	Sell
2022-05-10	Herabstufung	Piper Sandler	Neutral → Underweight
2022-03-01	Herabstufung	BofA Securities	Buy → Neutral
2022-03-01	Herabstufung	Raymond James	Outperform → Mkt Perform
2021-06-15	Eingeleitet	Citigroup	Neutral
2021-04-07	Fortgesetzt	RBC Capital Mkts	Outperform
2021-03-08	Herabstufung	Goldman	Buy → Neutral
2021-03-02	Herabstufung	JP Morgan	Overweight → Neutral
2021-02-26	Herabstufung	Wolfe Research	Outperform → Peer Perform
2021-01-05	Eingeleitet	Argus	Hold
2020-12-14	Eingeleitet	Bernstein	Mkt Perform

Alle ansehen

Viatris Inc Aktie (VTRS) Neueste Nachrichten

Finanzdaten der Viatris Inc-Aktie (VTRS)

Viatris Inc (VTRS)

Viatris Inc Stock (VTRS) Company Profile

Compare VTRS vs TAK, ZTS, HLN, TEVA, UTHR

Viatris Inc Stock (VTRS) Upgrades & Downgrades

Viatris Inc Aktie (VTRS) Neueste Nachrichten

Viatris Inc. (VTRS) Discusses Long-Term Growth Outlook and Portfolio Strategy Across Generics, Established Brands and Innovative MedicinesSlideshow (NASDAQ:VTRS) 2026-03-25 - Seeking Alpha

Viatris Inc. stock rises Wednesday, outperforms market - MarketWatch

Viatris Named to 3BL’s 100 Best Corporate Citizens of 2023 Ranking - CSRwire

Viatris Insider Sold Shares Worth $283,539, According to a Recent SEC Filing - marketscreener.com

Analysts Are Bullish on Top Healthcare Stocks: Siemens Healthineers AG (SEMHF), Viatris (VTRS) - The Globe and Mail

Top Viatris Executive Makes Notable Move With Insider Stock Sale - TipRanks

Viatris Inc officer Campbell sells $283k in shares - Investing.com

Viatris (VTRS) insider trims stake with 21,350-share open-market sale - Stock Titan

Global cardiovascular leaders convene as Viatris joins ACC26 event in New Orleans - Traders Union

Viatris sets long-term targets ahead of investor event - MSN

[144] Viatris Inc SEC Filing - Stock Titan

Barclays raises Viatris stock price target on pipeline potential By Investing.com - Investing.com Australia

Barclays raises Viatris stock price target on pipeline potential - Investing.com

Viatris’ Effexor Approved in Japan for Generalized Anxiety Disorder - Contract Pharma

Barclays Adjusts Viatris Price Target to $17 From $15, Maintains Overweight Rating - marketscreener.com

Viatris Stock: Is VTRS Outperforming the Health Care Sector? - Barchart.com

Viatris Says Japan Regulator Approves Effexor for Generalized Anxiety Disorder in Adults - marketscreener.com

Viatris wins Japan approval for Effexor to treat anxiety disorder - Investing.com

Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD) - PR Newswire

Levi & Korsinsky Notifies Shareholders of Viatris Inc.(VTRS) of a Class Action Lawsuit and an Upcoming Deadline - The National Law Review

Viatris Advances Innovative Portfolio with Approval of Effexor in Japan for Adults with Generalized Anxiety Disorder (GAD) - Bitget

How (VTRS) Movements Inform Risk Allocation Models - Stock Traders Daily

What are analysts saying about Viatris Inc (VTRS) stock? - MSN

Viatris shares break six-session winning streak - MSN

Will Viatris’ 2030 Capital Return And Growth Blueprint Change Viatris' (VTRS) Narrative - Yahoo Finance

Jefferies Keeps Their Buy Rating on Viatris (VTRS) - The Globe and Mail

Viatris Inc. stock falls Friday, underperforms market - MarketWatch

Theravance's Q4 Earnings and Revenues Miss Estimates - TradingView

Viatris: Is It A Credible Turnaround Or Overly Optimistic 2030 Plan? - Seeking Alpha

Will Viatris’ 2030 Capital and R&D Framework Reset the Core Investment Narrative for VTRS? - simplywall.st

VTRS Stock Price, Quote & Chart | VIATRIS INC (NASDAQ:VTRS) - ChartMill

Viatris Inc. stock falls Thursday, underperforms market - MarketWatch

Viatris sets revenue growth targets through 2030 By Investing.com - Investing.com India

Viatris sets revenue growth targets through 2030 - Investing.com

Viatris : VTRS Investor Event Presentation FINAL (1) - marketscreener.com

$11B cash by 2030 gives Viatris room for deals and shareholder returns - Stock Titan

Tranche Update on Viatris Inc.'s Equity Buyback Plan announced on February 28, 2022. - marketscreener.com

Class Action Filed Against Viatris Inc. (VTRS) Seeking Recovery for InvestorsContact Levi & Korsinsky - The National Law Review

Viatris Inc. Sued for Securities Law ViolationsInvestors Shoul - The National Law Review

Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030 - Bitget

UBS Cite Efficient Capital Allocation and Rising Profits in Viatris Inc. (VTRS) Upgrade - MSN

Analysts optimistic ahead of Viatris' Q4 earnings driven by healthy drug pipeline - MSN

Antiretroviral Therapy Market Critical Analysis with Expert Opinion| Gilead Sciences, Viatris, AbbVie - openPR.com

Viatris, Opus gain as FDA to review label expansion for eyecare drug - MSN

Viatris Inc. stock rises Monday, outperforms market - MSN

Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch

What Are Analysts Saying About Viatris Inc (VTRS) Stock? - Insider Monkey

Henrietta Lacks family settles lawsuit against Viatris over cell use - WBFF

Assessing Viatris (VTRS) Valuation After Mixed Short And Long Term Share Price Moves - Yahoo Finance

VTRS SEC FilingsViatris Inc Ord Shs 10-K, 10-Q, 8-K Forms - Stock Titan

UBS and BofA Lift Price Targets on Viatris (VTRS) - Insider Monkey

Finanzdaten der Viatris Inc-Aktie (VTRS)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie VTRS